TerminatedNCT03121586

Pimavanserin for schizophrenia

Medication studyAges 18+Multiple countries

The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.

Listed locations: Phoenix and 160 more locationsSee all locations and recruitment
Study phase: Phase 3

Get this study by email

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 2017

Recruitment status: Terminated
Enrollment listed in the registry: 995
Sponsor: ACADIA Pharmaceuticals Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States, Canada, Argentina, ...
Age range: Over 18 Years
Official registry ID: NCT03121586
Official title: Show the full official title
A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Recruitment & locations

Terminated

Phoenix, United States · Little Rock, United States · Rogers, United States

99 more locations

Bellflower, United States
Culver City, United States
Lemon Grove, United States
San Diego, United States
Santa Ana, United States
Torrance, United States
Hialeah, United States
Lauderhill, United States
Miami, United States
Atlanta, United States
Marietta, United States
Chicago, United States
Hoffman Estates, United States
Lake Charles, United States
Las Vegas, United States
Berlin, United States
Albuquerque, United States
Cedarhurst, United States
Jamaica, United States
Rochester, United States
Charlotte, United States
Durham, United States
Oklahoma City, United States
Downingtown, United States
Irving, United States
Richardson, United States
Salt Lake City, United States
Buenos Aires, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Ciudad Autonoma de Buenos Aire, Argentina
Córdoba, Argentina
La Plata, Argentina
Mendoza, Argentina
Burgas, Bulgaria
Kardzhali, Bulgaria
Kazanlak, Bulgaria
Lovech, Bulgaria
Pazardzhik, Bulgaria
Pleven, Bulgaria
Plovdiv, Bulgaria
Sofia, Bulgaria
Targovishte, Bulgaria
Tsarev Brod, Bulgaria
Varna, Bulgaria
Veliko Tarnovo, Bulgaria
Vratsa, Bulgaria
Chatham, Canada
Montreal, Canada
Zagreb, Croatia
Hradec Králové, Czechia
Klecany, Czechia
Pilsen, Czechia
Prague, Czechia
Říčany, Czechia
Kalocsa, Hungary
Budapest, Hungary
Pécs, Hungary
Milan, Italy
Torino, Italy
Kaunas, Lithuania
Šilutė, Lithuania
Vilnius, Lithuania
Bialystok, Poland
Bydgoszcz, Poland
Gdansk, Poland
Lublin, Poland
Pruszków, Poland
Plekhanovo, Russia
Tonnel’nyy, Russia
Arkhangelsk, Russia
Moscow, Russia
Saint Petersburg, Russia
Smolensk, Russia
Stavropol, Russia
Tomsk, Russia
Voronezh, Russia
Yaroslavl, Russia
Belgrade, Serbia
Kovin, Serbia
Kragujevac, Serbia
Niš, Serbia
Novi Kneževac, Serbia
Barcelona, Spain
Madrid, Spain
Oviedo, Spain
Valladolid, Spain
Zamora, Spain
Odesa, Ukraine
Dnipro, Ukraine
Hlevakha, Ukraine
Kharkiv, Ukraine
Kherson, Ukraine
Kyiv, Ukraine
Nove, Ukraine
Smila, Ukraine
Uzhhorod, Ukraine
Vinnytsia, Ukraine
Czechia
Russia

Interested in joining this study?

FAQ

Questions about this study

Who is behind this study?

The study sponsor is ACADIA Pharmaceuticals Inc.

Does this study involve medication?

Yes. The study involves medication, including Pimavanserin.

Who can participate?

This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies